FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Articles / Read Article

Print

Monroe Capital Supports Altaris Capital Partners’ Acquisition of Kindeva Drug Delivery

Date: May 04, 2020 @ 09:13 AM
Filed Under: Mergers & Acquisitions

Monroe Capital LLC announced it acted as Co-Syndication Agent in the funding of a senior credit facility and equity co-investment to support the acquisition of Kindeva Drug Delivery L.P. (“Kindeva”) by Altaris Capital Partners.

Based outside of St. Paul, Minnesota, Kindeva is a unique Contract Development and Manufacturing Organization (“CDMO”) focused on both drugs and their delivery devices, particularly inhalation, including asthma inhalers; transdermal, or patches that deliver drugs; and other systems. The company’s microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for COVID-19 vaccines and other difficult-to-deliver therapies. Kindeva is a carve-out of the 3M Drug Delivery Systems Division. 3M is a diversified industrials conglomerate operating across multiple sectors, including consumer, telecommunications, security, healthcare and transportation.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.